logo-loader
BioPorto

BioPorto submits kidney-injury test in children to FDA

BioPorto A/S (CPH:BIOPOR) CEO Peter Eriksen and US President Amy Winslow tell Proactive Investors the Danish company has submitted an application to FDA for approval of its proprietary NGAL Test that assesses the risk of acute kidney injury in children under 21.

Winslow adds color to the way in which the company will commercialize the diagnostic pending approval.

Quick facts: BioPorto

Price: £0.00

Market: NASDAQ OMX
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Enertopia completes spring and summer testing program,...

Enertopia Corp (CSE: TOP) President and CEO Robert McAllister sat down with Steve Darling from Proactive Vancouver to bring news the company has wrapped up their spring and summer testing program for pre-strip reagent testing to control impurity levels in the Upper Oxide and Reduced drilled...

18 hours, 48 minutes ago

2 min read